KYIV. Jan 24 (Interfax-Ukraine) – Pharmaceutical manufacturers are alarmed with a possibility of disappearance of medicines under the reimbursement program from the Ukrainian market, European Business Association (EBA) Health Care Committee Executive Director Natalia Serhienko said at a press conference at Interfax-Ukraine on Tuesday.

"Some medicines in three international nonproprietary names (INN) which we are speaking about could disappear. Distributors have stopped ordering the medicines from the reimbursement list from manufacturers. Manufacturers are not ready to supply some medicines. Today pharmacies do not take some medicines from distributors as they do not know if they were able to sell them after February 1," she said.

Board member of the Association of Pharmaceutical Manufacturers of Ukraine and Interchem Head Anatoliy Reder expressed hope that with the introduction of the reimbursement scheme these 21 INN that are to be reimbursed would not start disappearing from the Ukrainian market.

"I really hope that the ministry will react to a lot of requests to explain [reimbursement] and I really hope that explanations would be rational, right and logical and nothing would disappear," Reder said.

Development Director at Business Credit marketing company Andriy Tsurkan said that in 2016 pharmacy sales of mono-preparations which cost is to be reimbursed came to UAH 1.7 billion in money terms and hospital sales reached UAH 231.6 million.

"There are not only mono-molecules. There are combinations of these molecules and no one speaks about them. If we speak about them, this is UAH 400 million more of retail pharmacy sales and UAH 10 million of hospital sales. No one is going to reimburse coformulated medicines," he said.